These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 5001942)

  • 41. Human immunity to Neisseria gonorrhoeae: acquired serum opsonic antibodies.
    Bisno AL; Ofek I; Beachey EH; Chandler RW; Curran JW
    J Lab Clin Med; 1975 Aug; 86(2):221-9. PubMed ID: 807662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of Pseudomonas alginate on rat alveolar macrophage phagocytosis and bacterial opsonization.
    Oliver AM; Weir DM
    Clin Exp Immunol; 1985 Jan; 59(1):190-6. PubMed ID: 3918817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of IgG subclass antibodies in chronic infection: the case of cystic fibrosis.
    Moss RB
    N Engl Reg Allergy Proc; 1988; 9(1):57-61. PubMed ID: 3362109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complement-mediated phagocytosis of Pseudomonas aeruginosa.
    Peterson PK; Kim Y; Schmeling D; Lindemann M; Verhoef J; Quie PG
    J Lab Clin Med; 1978 Dec; 92(6):883-94. PubMed ID: 105067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages.
    Thomassen MJ; Boxerbaum B; Demko CA; Kuchenbrod PJ; Dearborn DG; Wood RE
    Pediatr Res; 1979 Sep; 13(9):1085-8. PubMed ID: 116188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pulmonary host defenses. II. Interaction of respiratory antibodies with Pseudomonas aeruginosa and alveolar macrophages.
    Reynolds HY; Thompson RE
    J Immunol; 1973 Aug; 111(2):369-80. PubMed ID: 4197983
    [No Abstract]   [Full Text] [Related]  

  • 48. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
    Young LS; Armstrong D
    J Infect Dis; 1972 Sep; 126(3):257-76. PubMed ID: 4626509
    [No Abstract]   [Full Text] [Related]  

  • 49. Defective opsonization. A common immunity deficiency.
    Soothill JF; Harvey BA
    Arch Dis Child; 1976 Feb; 51(2):91-9. PubMed ID: 769701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.
    Van de Weert-van Leeuwen PB; Van Meegen MA; Speirs JJ; Pals DJ; Rooijakkers SH; Van der Ent CK; Terheggen-Lagro SW; Arets HG; Beekman JM
    Am J Respir Cell Mol Biol; 2013 Sep; 49(3):463-70. PubMed ID: 23617438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
    Holby N; Olling S
    Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autoantibodies in serum and sputum from patients with cystic fibrosis.
    Schiøtz PO; Egeskjold EM; Høiby N; Permin H
    Acta Pathol Microbiol Scand C; 1979 Oct; 87(5):319-24. PubMed ID: 117671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell-mediated immunity in patients with cystic fibrosis.
    Gibbons A; Allan JD; Holzel A; McFarlane H
    Br Med J; 1976 Jan; 1(6002):120-2. PubMed ID: 813805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis.
    Moss RB; Lewiston NJ
    Am Rev Respir Dis; 1980 Jan; 121(1):23-9. PubMed ID: 6766286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis.
    Schiøtz PO; Høiby N; Permin H; Wiik A
    Acta Pathol Microbiol Scand C; 1979 Jun; 87C(3):229-33. PubMed ID: 113981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Phagocytosis defect of granulocytes in cystic fibrosis].
    Böhme B
    Helv Paediatr Acta; 1972 Dec; 27(6):607-12. PubMed ID: 4648851
    [No Abstract]   [Full Text] [Related]  

  • 57. The role of antibody and complement in phagocytosis by rabbit alveolar macrophages.
    Murphey SA; Root RK; Schreiber AD
    J Infect Dis; 1979 Dec; 140(6):896-903. PubMed ID: 120385
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.
    Schaad UB; Lang AB; Wedgwood J; Buehlamnn U; Fuerer E
    Pediatr Res; 1990 May; 27(5):508-13. PubMed ID: 2111907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pulmonary nonspecific defense mechanisms in cystic fibrosis. I. Phagocytic capacity of alveolar macrophages and neutrophils.
    Cassino RJ; Sordelli DO; Macri CN; Kohan M; Dillon MH; Pivetta OH
    Pediatr Res; 1980 Nov; 14(11):1212-5. PubMed ID: 7454434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
    Pier GB; Takeda S; Grout M; Markham RB
    J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.